Alan Scott Enterprises Ltd Q3 FY26 — ₹34.45 Cr Sales, -142% ROE, EV/EBITDA 49x: Healthcare Hero or Hygiene Horror?
1. At a Glance
Alan Scott Enterprises Ltd is one of those stocks that looks like a startup pitch deck trapped inside a listed company. ₹160 Cr market cap, ₹279 stock price, a 3-year return of 110%, and yet—drumroll—negative profits, negative ROE (-142%), and interest coverage that looks like it skipped leg day (-0.22).
Latest quarterly sales clocked in at ₹8.26 Cr, up 5.76% QoQ, while PAT politely refused to cooperate at -₹0.70 Cr. EV/EBITDA sits at a spicy 49x, which is bold for a company still negotiating with gravity on profitability.
Promoters hold 63.5%, debt is ₹11.7 Cr, and book value is a humble ₹14.2—making the stock trade at ~20x book. That’s luxury valuation for a balance sheet still figuring out oxygen—ironically, for an oxygen concentrator company.
So… turnaround in progress or optimism on EMI? Let’s dig. 👇
2. Introduction
Alan Scott Enterprises Ltd was incorporated in 1994, which means it has survived liberalisation, dot-com bubbles, global financial crises, COVID, and still managed to remain… financially mysterious.
The company operates in health and hygiene products—air purifiers, oxygen concentrators, anti-bacterial equipment—basically everything that became fashionable during COVID and then quietly moved to the corner shelf once the panic subsided.
Sales have grown fast (185% CAGR over 3 years), but profits have not received the memo. Losses continue, depreciation is rising, interest costs are climbing, and ROE is deep in the Mariana Trench.
Yet the stock price has tripled in three years. Why? Preferential issues, JV announcements, subsidiaries, retail stores, and just enough “future story” to keep optimism alive.
Is this a phoenix in the making—or a hygiene brand with valuation allergies? Keep reading.
3. Business Model – WTF Do They Even Do?
In simple terms: Alan Scott wants to sell clean air, clean surfaces, and clean hope.
Core Products:
5 Petals Air Purifier+ Claims 99.9% protection against viruses, bacteria, fungus, yeasts, and probably bad vibes too. Uses “8 technologies”—which sounds impressive, though your lungs only care about results.
Other income keeps popping up like that friend who always “pays next time”.
This is not yet a scalable, cash-generating healthcare platform. It’s more like a product-first company still auditioning for operating leverage.
4. Financials Overview (Quarterly Results)
📊 Quarterly Comparison Table (₹ Cr)
Metric
Latest Qtr (Dec’25)
YoY Qtr (Dec’24)
Prev Qtr (Sep’25)
YoY %
QoQ %
Revenue
8.26
7.81
8.81
+5.8%
-6.2%
EBITDA
-0.11
0.19
0.61
NA
NA
PAT
-0.70
+0.55
-0.90
-213%
+22%
EPS (₹)
-1.22
+1.15
-1.14
NA
NA
Commentary: Revenue is walking forward. Profits are moonwalking backwards. EBITDA turning negative again after flirting with positivity is not the character development we wanted.
5. Valuation Discussion – Fair Value Range
Method 1: P/E
EPS (TTM): -₹4.41 → P/E undefined. Market is clearly pricing hope, not earnings.
Method 2: EV/EBITDA
EV: ₹171 Cr
EBITDA (TTM): ~₹2.25 Cr
EV/EBITDA: ~49x
That’s premium SaaS territory… for a loss-making manufacturing company.
Method 3: DCF (Educational)
Given negative cash flows and unstable margins, any DCF becomes fiction with Excel fonts.
Fair Value Range (Educational Only):
₹120 – ₹180
This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
₹6.75 Cr raised via preferential issue at ₹250.
Acquired stakes in five entities for ₹4.83 Cr.
JV with Nanoveu (Singapore) to distribute antibacterial surface protectants.
New subsidiaries for retail and hygiene manufacturing.
